Skip Navigation

Annals of Oncology 2006 17(Supplement 4):iv12-iv14; doi:10.1093/annonc/mdj992
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 4 iss...
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zelenetz, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelenetz, A. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Mantle cell lymphoma: an update on management

A. D. Zelenetz

Division of Hematologic Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY, USA

Correspondence to: A. D. Zelenetz, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel +1-212-639-2656; Fax +1-212-772-8550; E-mail: A-Zelenetz{at}ski.mskcc.org

Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.

Key words: mantle cell lymphoma, rituximab, autologous stem cell transplantation, radioimmunotherapy, targeted therapies, bortezomib, temsirolimus, flavopiridol


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
G. V. Hegde, C. M. Munger, K. Emanuel, A. D. Joshi, T. C. Greiner, D. D. Weisenburger, J. M. Vose, and S. S. Joshi
Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma
Mol. Cancer Ther., June 1, 2008; 7(6): 1450 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Blood, June 15, 2007; 109(12): 5455 - 5462.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.